Abstract
An aqueous gel formulation containing solubilized clindamycin phosphate 1.2% and a stable combination of both solubilized and crystalline tretinoin 0.025% (clin/tret) has been evaluated in 3 pivotal phase 3 studies, among other studies including a 52-week trial. The pivotal studies enrolled 4550 participants 12 years and older with mild, moderate, and severe acne vulgaris. The combination clin/tret gel was effective in reducing both inflammatory and noninflammatory lesions and was well-tolerated. This article reviews important vehicle characteristics of the combination gel as well as formulation stability and tolerability data that are potentially clinically relevant.
MeSH terms
-
Acne Vulgaris / drug therapy*
-
Administration, Cutaneous
-
Anti-Bacterial Agents* / administration & dosage
-
Anti-Bacterial Agents* / adverse effects
-
Anti-Bacterial Agents* / chemistry
-
Anti-Bacterial Agents* / pharmacology
-
Benzoyl Peroxide / pharmacology
-
Clindamycin / administration & dosage
-
Clindamycin / adverse effects
-
Clindamycin / analogs & derivatives*
-
Clindamycin / chemistry
-
Clindamycin / pharmacology
-
Dermatitis, Irritant / etiology
-
Dermatologic Agents* / administration & dosage
-
Dermatologic Agents* / adverse effects
-
Dermatologic Agents* / chemistry
-
Dermatologic Agents* / pharmacology
-
Drug Combinations
-
Drug Interactions
-
Drug Stability
-
Gels
-
Humans
-
Pharmaceutical Vehicles / chemistry
-
Pharmaceutical Vehicles / pharmacology
-
Skin Absorption
-
Tretinoin* / administration & dosage
-
Tretinoin* / adverse effects
-
Tretinoin* / chemistry
-
Tretinoin* / pharmacology
Substances
-
Anti-Bacterial Agents
-
Dermatologic Agents
-
Drug Combinations
-
Gels
-
Pharmaceutical Vehicles
-
Clindamycin
-
Tretinoin
-
clindamycin phosphate
-
Benzoyl Peroxide